Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis.
- DOI
- 10.1016/j.bneo.2025.100165
- Published
- 2025 Nov
- Container
- Blood neoplasia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bneo.2025.100165,
title = {Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis.},
author = {Yacoub A and Ali H and Gupta V and Wang ES and Patnaik MM and Schiller GJ and Taparia M and Mughal TI and Lindsay R and Galleu A and Gupta I and Pemmaraju N},
year = {2025},
journal = {Blood neoplasia},
doi = {10.1016/j.bneo.2025.100165},
url = {https://doi.org/10.1016/j.bneo.2025.100165}
}RIS
TY - JOUR TI - Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. AU - Yacoub A AU - Ali H AU - Gupta V AU - Wang ES AU - Patnaik MM AU - Schiller GJ AU - Taparia M AU - Mughal TI AU - Lindsay R AU - Galleu A AU - Gupta I AU - Pemmaraju N PY - 2025 JO - Blood neoplasia DO - 10.1016/j.bneo.2025.100165 UR - https://doi.org/10.1016/j.bneo.2025.100165 ER -
APA
A, Y., H, A., V, G., ES, W., MM, P., GJ, S., M, T., TI, M., R, L., A, G., I, G., & N, P. (2025). Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis.. Blood neoplasia. https://doi.org/10.1016/j.bneo.2025.100165
Source records
- pubmed · retrieved 2026-09-26T21:21:42.816Z